Complement Therapeutics GmbH (CTx), a clinical-stage biotechnology company developing next-generation therapeutics for complement-mediated diseases, today announced that the U.S. Food and Drug ...

The FDA granted fast track designation for CTx001, an investigational gene therapy candidate for geographic atrophy secondary ...

The complement component C5a and its receptors, C5aR1 and C5aR2, are central to the orchestration of innate immunity. C5a is a potent anaphylatoxin generated during complement activation, acting as a ...

Individuals who develop antibodies against the GluN1 subunit of NMDA receptors can develop NMDA receptor encephalitis (NMDARE), which can lead to psychosis, cognitive deficits and movement disorders.

Global understanding of complement has shifted and developed since the 21st century: from our idea of a blood-based antibiotic system to a global regulator of immunity and tissue homeostasis. Recent ...